MICHELLE MCQUILLAN: Open Payments
NPI 1013533819 · O'FALLON, IL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,826 in 83 payments from 27 companies in 2025. Trend: 2023 $1,786 · 2024 $1,960 · 2025 $1,826
Food & beverage: $1,740Education: $86
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation | 16 | $341 |
| Janssen Biotech, Inc. | 8 | $194 |
| Merck Sharp & Dohme LLC | 5 | $125 |
| GENZYME CORPORATION | 5 | $109 |
| ABBVIE INC. | 5 | $104 |
| Eisai Inc. | 4 | $95 |
| GlaxoSmithKline, LLC. | 4 | $91 |
| AstraZeneca Pharmaceuticals LP | 4 | $91 |
| Aveo Pharmaceuticals, Inc. | 4 | $83 |
| Lilly USA, LLC | 3 | $54 |
Products named: RYBREVANT, KISQALI, KEYTRUDA, Lenvima, Fabhalta, FOTIVDA, EPKINLY, SARCLISA.
Industry payments across IL — which companies pay providers there.
